MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP)

Ali S. Arbab, Adarsh Shankar, Nadimpalli R.S. Varma, Dorrah Deeb, Xiaohua Gao, ASM S.M. Iskander, Branislava Janic, Meser M. Ali, Subhash C. Gautam

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The current method to determine the efficacy of chemoprevention in TRAMP mouse model of carcinoma of prostate (CaP) is by extracting and weighing the prostate at different time points or by immunohistochemistry analysis. Non-invasive determination of volumes of prostate glands and seminal vesicles before, during and after treatment would be valuable in investigating the efficacy of newer chemopreventive agents in CaP. The purpose of this study was to determine whether in vivo magnetic resonance imaging (MRI) using a 3 tesla clinical MRI system can be used to follow the effect of chemoprevention in TRAMP model of mouse CaP.Methods: Mice were randomized into control and treated groups. The animals in treated group received 10 μmol/kg of CDDO, 5 days a week for 20 weeks. Animals underwent in vivo MRI of prostate gland and seminal vesicles by a clinical 3 Tesla MRI system just before (at 5 weeks), during and at the end of treatment, at 25 weeks. T1-weighted and fat saturation (FATSAT) multiecho fast spin echo T2- weighted images (T2WI) were acquired. Volume of the prostate glands and seminal vesicles was determined from MR images. T2 signal intensity changes in the seminal vesicles were determined by subtracting higher echo time (TE) from lower TE T2WI. Following treatments all animals were sacrificed, prostate and seminal vesicles collected, and the tissues prepared for histological staining. All data were expressed as mean ± 1 standard deviation. Two-way or multivariate analysis of variance followed by post-hoc test was applied to determine the significant differences. A p-value of <0.05 was considered significant.Results: Histological analysis indicated tumor in 100% of control mice, whereas 10% of the treated mice showed tumor in prostate gland. Both MRI and measured prostate weights showed higher volume/weight in control mouse group. MRI showed significantly higher volume of seminal vesicles in control animals and T2 signal intensity changes in seminal vesicles of control mice indicating higher number of tumor foci, which was also proven by histology.Conclusions: In vivo MRI is helpful in determining the efficacy of chemoprevention of prostate cancer in TRAMP mice.

Original languageEnglish (US)
Article number21
JournalBMC Medical Imaging
Volume11
DOIs
StatePublished - Dec 13 2011

Fingerprint

Chemoprevention
Transgenic Mice
Prostate
Adenocarcinoma
Magnetic Resonance Imaging
Seminal Vesicles
Carcinoma
Weights and Measures
Neoplasms
Control Groups
Prostatic Neoplasms
Histology
Analysis of Variance
Therapeutics
Multivariate Analysis
Immunohistochemistry
Fats

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Arbab, A. S., Shankar, A., Varma, N. R. S., Deeb, D., Gao, X., Iskander, ASM. S. M., ... Gautam, S. C. (2011). MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP). BMC Medical Imaging, 11, [21]. https://doi.org/10.1186/1471-2342-11-21

MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP). / Arbab, Ali S.; Shankar, Adarsh; Varma, Nadimpalli R.S.; Deeb, Dorrah; Gao, Xiaohua; Iskander, ASM S.M.; Janic, Branislava; Ali, Meser M.; Gautam, Subhash C.

In: BMC Medical Imaging, Vol. 11, 21, 13.12.2011.

Research output: Contribution to journalArticle

Arbab, AS, Shankar, A, Varma, NRS, Deeb, D, Gao, X, Iskander, ASMSM, Janic, B, Ali, MM & Gautam, SC 2011, 'MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP)', BMC Medical Imaging, vol. 11, 21. https://doi.org/10.1186/1471-2342-11-21
Arbab, Ali S. ; Shankar, Adarsh ; Varma, Nadimpalli R.S. ; Deeb, Dorrah ; Gao, Xiaohua ; Iskander, ASM S.M. ; Janic, Branislava ; Ali, Meser M. ; Gautam, Subhash C. / MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP). In: BMC Medical Imaging. 2011 ; Vol. 11.
@article{9b6fea3a254047ba8643143b6502e03d,
title = "MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP)",
abstract = "Background: The current method to determine the efficacy of chemoprevention in TRAMP mouse model of carcinoma of prostate (CaP) is by extracting and weighing the prostate at different time points or by immunohistochemistry analysis. Non-invasive determination of volumes of prostate glands and seminal vesicles before, during and after treatment would be valuable in investigating the efficacy of newer chemopreventive agents in CaP. The purpose of this study was to determine whether in vivo magnetic resonance imaging (MRI) using a 3 tesla clinical MRI system can be used to follow the effect of chemoprevention in TRAMP model of mouse CaP.Methods: Mice were randomized into control and treated groups. The animals in treated group received 10 μmol/kg of CDDO, 5 days a week for 20 weeks. Animals underwent in vivo MRI of prostate gland and seminal vesicles by a clinical 3 Tesla MRI system just before (at 5 weeks), during and at the end of treatment, at 25 weeks. T1-weighted and fat saturation (FATSAT) multiecho fast spin echo T2- weighted images (T2WI) were acquired. Volume of the prostate glands and seminal vesicles was determined from MR images. T2 signal intensity changes in the seminal vesicles were determined by subtracting higher echo time (TE) from lower TE T2WI. Following treatments all animals were sacrificed, prostate and seminal vesicles collected, and the tissues prepared for histological staining. All data were expressed as mean ± 1 standard deviation. Two-way or multivariate analysis of variance followed by post-hoc test was applied to determine the significant differences. A p-value of <0.05 was considered significant.Results: Histological analysis indicated tumor in 100{\%} of control mice, whereas 10{\%} of the treated mice showed tumor in prostate gland. Both MRI and measured prostate weights showed higher volume/weight in control mouse group. MRI showed significantly higher volume of seminal vesicles in control animals and T2 signal intensity changes in seminal vesicles of control mice indicating higher number of tumor foci, which was also proven by histology.Conclusions: In vivo MRI is helpful in determining the efficacy of chemoprevention of prostate cancer in TRAMP mice.",
author = "Arbab, {Ali S.} and Adarsh Shankar and Varma, {Nadimpalli R.S.} and Dorrah Deeb and Xiaohua Gao and Iskander, {ASM S.M.} and Branislava Janic and Ali, {Meser M.} and Gautam, {Subhash C.}",
year = "2011",
month = "12",
day = "13",
doi = "10.1186/1471-2342-11-21",
language = "English (US)",
volume = "11",
journal = "BMC Medical Imaging",
issn = "1471-2342",
publisher = "BioMed Central",

}

TY - JOUR

T1 - MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP)

AU - Arbab, Ali S.

AU - Shankar, Adarsh

AU - Varma, Nadimpalli R.S.

AU - Deeb, Dorrah

AU - Gao, Xiaohua

AU - Iskander, ASM S.M.

AU - Janic, Branislava

AU - Ali, Meser M.

AU - Gautam, Subhash C.

PY - 2011/12/13

Y1 - 2011/12/13

N2 - Background: The current method to determine the efficacy of chemoprevention in TRAMP mouse model of carcinoma of prostate (CaP) is by extracting and weighing the prostate at different time points or by immunohistochemistry analysis. Non-invasive determination of volumes of prostate glands and seminal vesicles before, during and after treatment would be valuable in investigating the efficacy of newer chemopreventive agents in CaP. The purpose of this study was to determine whether in vivo magnetic resonance imaging (MRI) using a 3 tesla clinical MRI system can be used to follow the effect of chemoprevention in TRAMP model of mouse CaP.Methods: Mice were randomized into control and treated groups. The animals in treated group received 10 μmol/kg of CDDO, 5 days a week for 20 weeks. Animals underwent in vivo MRI of prostate gland and seminal vesicles by a clinical 3 Tesla MRI system just before (at 5 weeks), during and at the end of treatment, at 25 weeks. T1-weighted and fat saturation (FATSAT) multiecho fast spin echo T2- weighted images (T2WI) were acquired. Volume of the prostate glands and seminal vesicles was determined from MR images. T2 signal intensity changes in the seminal vesicles were determined by subtracting higher echo time (TE) from lower TE T2WI. Following treatments all animals were sacrificed, prostate and seminal vesicles collected, and the tissues prepared for histological staining. All data were expressed as mean ± 1 standard deviation. Two-way or multivariate analysis of variance followed by post-hoc test was applied to determine the significant differences. A p-value of <0.05 was considered significant.Results: Histological analysis indicated tumor in 100% of control mice, whereas 10% of the treated mice showed tumor in prostate gland. Both MRI and measured prostate weights showed higher volume/weight in control mouse group. MRI showed significantly higher volume of seminal vesicles in control animals and T2 signal intensity changes in seminal vesicles of control mice indicating higher number of tumor foci, which was also proven by histology.Conclusions: In vivo MRI is helpful in determining the efficacy of chemoprevention of prostate cancer in TRAMP mice.

AB - Background: The current method to determine the efficacy of chemoprevention in TRAMP mouse model of carcinoma of prostate (CaP) is by extracting and weighing the prostate at different time points or by immunohistochemistry analysis. Non-invasive determination of volumes of prostate glands and seminal vesicles before, during and after treatment would be valuable in investigating the efficacy of newer chemopreventive agents in CaP. The purpose of this study was to determine whether in vivo magnetic resonance imaging (MRI) using a 3 tesla clinical MRI system can be used to follow the effect of chemoprevention in TRAMP model of mouse CaP.Methods: Mice were randomized into control and treated groups. The animals in treated group received 10 μmol/kg of CDDO, 5 days a week for 20 weeks. Animals underwent in vivo MRI of prostate gland and seminal vesicles by a clinical 3 Tesla MRI system just before (at 5 weeks), during and at the end of treatment, at 25 weeks. T1-weighted and fat saturation (FATSAT) multiecho fast spin echo T2- weighted images (T2WI) were acquired. Volume of the prostate glands and seminal vesicles was determined from MR images. T2 signal intensity changes in the seminal vesicles were determined by subtracting higher echo time (TE) from lower TE T2WI. Following treatments all animals were sacrificed, prostate and seminal vesicles collected, and the tissues prepared for histological staining. All data were expressed as mean ± 1 standard deviation. Two-way or multivariate analysis of variance followed by post-hoc test was applied to determine the significant differences. A p-value of <0.05 was considered significant.Results: Histological analysis indicated tumor in 100% of control mice, whereas 10% of the treated mice showed tumor in prostate gland. Both MRI and measured prostate weights showed higher volume/weight in control mouse group. MRI showed significantly higher volume of seminal vesicles in control animals and T2 signal intensity changes in seminal vesicles of control mice indicating higher number of tumor foci, which was also proven by histology.Conclusions: In vivo MRI is helpful in determining the efficacy of chemoprevention of prostate cancer in TRAMP mice.

UR - http://www.scopus.com/inward/record.url?scp=83255164935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83255164935&partnerID=8YFLogxK

U2 - 10.1186/1471-2342-11-21

DO - 10.1186/1471-2342-11-21

M3 - Article

C2 - 22165848

AN - SCOPUS:83255164935

VL - 11

JO - BMC Medical Imaging

JF - BMC Medical Imaging

SN - 1471-2342

M1 - 21

ER -